<DOC>
	<DOCNO>NCT00775593</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , clofarabine , work different way stop growth cancer cell , either kill cell stop dividing . Temsirolimus may stop growth cancer cell block enzymes need cell growth . Giving clofarabine together temsirolimus may kill cancer cell . PURPOSE : This phase II trial study well give clofarabine together temsirolimus work treat old patient relapse refractory acute myeloid leukemia .</brief_summary>
	<brief_title>Clofarabine Temsirolimus Treating Older Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine complete response rate old patient relapse refractory acute myeloid leukemia treat low-dose clofarabine temsirolimus . Secondary - To determine tolerability safety regimen . - To determine duration response . - To determine duration survival . OUTLINE : This multicenter study . - Induction therapy : Patients receive clofarabine IV 1 hour day 1-5 temsirolimus IV 30 minute day 1 , 8 , 15 . Treatment continue 1-2 course absence disease progression unacceptable toxicity . - Maintenance therapy : Patients achieve morphologic complete remission ( CR ) CR incomplete blood count recovery receive temsirolimus IV 30 minute day 1 8 month . Treatment continue 12 month absence disease progression unacceptable toxicity .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Cytologically confirm acute myeloid leukemia ( AML ) meeting follow criterion : At least 20 % blast bone marrow AML first relapse OR refractory one prior combination chemotherapy induction regimen No acute promyelocytic leukemia No blast transformation chronic myeloid leukemia myeloproliferative disorder No active CNS leukemia PATIENT CHARACTERISTICS : WHO performance status 02 Life expectancy ≥ 4 week Serum total bilirubin ≤ 1.5 time upper limit normal ( ULN ) * AST ALT ≤ 2.5 time ULN* Serum creatinine ≤ 1.0 mg/dL* OR estimate glomerular filtration rate &gt; 60 mL/min No active uncontrolled systemic infection No concurrent active malignancy No HIV positivity No severe concurrent medical condition psychiatric disorder would preclude study participation NOTE : *Unless due organ leukemic involvement PRIOR CONCURRENT THERAPY : See Disease Characteristics More 2 week since prior myelosuppressive chemotherapy At least 48 hour since prior hydroxyurea No prior clofarabine temsirolimus No prior allogeneic stem cell transplantation No investigational drug within past 30 day</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
</DOC>